Verismo Therapeutics Receives Fast Track Designation from FDA for SynKIR-110, a Novel CAR T Therapy for Mesothelioma Treatment

Verismo Therapeutics, a clinical-stage company specializing in CAR T technology, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its innovative drug, SynKIR-110. The drug is intended to treat mesothelioma, a serious and life-threatening condition. With this designation, SynKIR-110 may be eligible for Accelerated Approval and Priority Review if certain criteria are met.

Publish Date: 05-04-2023 Source: Verismo Therapeutics

Mesothelioma is a cancer caused by asbestos. It most commonly occurs in the lining of the lungs or the abdomen. The average life expectancy after diagnosis is 18 to 31 months, but treatment may improve the prognosis. Chest pain, general fatigue, and shortness of breath are all possible symptoms. Based on the tumour’s location, there are four main types of mesothelioma. Mesothelioma tumors are made up of various cell types. The three most common types of mesothelioma cells are epithelioid, sarcomatoid, and biphasic. About 75% of all mesothelioma cases are attributed to pleural mesothelioma, making it the most prevalent type.

In the USA, the incidence of mesothelioma ranges from 1 to cases per 100,000 population.

However, the current Mesothelioma treatment market share, market uptake, and attribute analysis concerning the most potential emerging therapies (Nivolumab, ADI-PEG, etc..) has been provided under the market outlook section of the study covering 8 MM countries; The United States, EU5 (Germany, Spain, France, Italy, UK) Japan and China.

In terms of pharmacologic therapies, several pharmaceutical products are being approved and under different phases of development for the Mesothelioma treatment. The key companies in the advanced development stage are Ono Pharmaceutical Co. Ltd, Polaris Group, etc..

Based on solid domain and business knowledge, Thelansis Knowledge Partners has published the market outlook forecast report on Mesothelioma to provide a clear understanding of disease area background, epidemiology, current and future competitions, the country-specific standard of care, and the complete market forecast for 2021 to 2032.

About Thelansis:

Thelansis specializes in pharmaceutical market outlook and market forecast reports. We published reports across the therapeutic area, including rare / ultra-rare and mainstream indications. Over the period, we have built a robust repository of 6,000+ Bio-pharma reports that cover Epidemiology studies and Market forecasting based on the KOL opinions.

Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the primary focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.